Resource utility {#S2}
================

Best's disease (BD) is an inherited degenerative maculopathy with no concrete therapies in human, which results in progressive loss of central vision. The FDEENTi002-A iPSC line may serve as a useful model for the pathogenesis study and drug screen of BD.

Resource details {#S3}
================

Best's disease (BD) is an autosomal dominant form of macular degeneration characterized by abnormal accumulation of lipofuscin-like materials within and beneath retinal pigment epithelium (RPE), which leads to progressive loss of central vision. It has been proved to be caused by mutations in *BEST1* gene, which encodes BESTROPHIN1 (BEST1), a protein predominantly expressed in RPE ([@R4]). Although a variety of mutations have been reported among BD patients, the mechanisms still remain unclear. In addition, different animal models reach a diversity of conclusions about the function of BEST1 protein in RPE, all of which underlines the need for a more suitable model for BD ([@R3]).

For this purpose, we established a BD-specific induced pluripotent stem cell (iPSC) line from a male patient carrying a heterozygous c.888C \> A mutation in *BEST1* gene, which results in the substitution of lysine for asparagine at condon 296 (p.N296K) ([@R2]). Peripheral blood mononuclear cells (PBMCs) were collected and reprogrammed by Sendai viral vectors expressing OCT4, SOX2, KLF4 and C-MYC ([@R1]). The newly established iPSC line, which wastermed FDEENTi002-A, presented a typical human embryonic stem cell (hESC) morphology ([Fig. 1A](#F1){ref-type="fig"}) and was positive for alkaline phosphatase staining ([Fig. 1B](#F1){ref-type="fig"}). The mutation of *BEST1* gene in FDEENTi002-A was confirmed by Sanger sequencing of the PCR product ([Fig. 1C](#F1){ref-type="fig"}). The iPSC line showed a normal diploid 46, XY karyotype (at passage 8) ([Fig. 1D](#F1){ref-type="fig"}) and was genetically authenticated with the donor's PBMCs by short tandem repeat (STR) analysis. The expression of major pluripotent markers (OCT4, SOX2, NANOG) was examined by immunocytochemical staining ([Fig. 1F](#F1){ref-type="fig"}). Quantitative polymerase chain reaction (qPCR) proved that OCT4, SOX2 and NANOG mRNA expression was at similar levels between FDEENTi002-A iPSC and hESC and was absent in the parental PBMCs ([Fig. 1E](#F1){ref-type="fig"}). Trilineage differentiation potential was confirmed in vitro by the expression of ectoderm (PAX6), mesoderm (MESP1) and endoderm (FOXA2) markers ([Fig. 1G](#F1){ref-type="fig"}). The absence of SeV genome and transgenes was confirmed at passage 11 by RT-PCR ([Fig. 1H](#F1){ref-type="fig"}). Mycoplasma contamination was excluded by PCR testing ([Fig. 1I](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}).

Materials and methods {#S4}
=====================

Cell culture and reprogramming {#S5}
------------------------------

PBMCs were isolated from the peripheral blood sample using Histopaque®−1077 (Sigma-Aldrich) and cultured in StemSpan SFEMIImedium (Stem Cell Technologies) supplemented with 100 ng/mL SCF, 100 ng/mL FLT-3 L, 20 ng/mL IL-3 and 20 ng/mL IL-6 cytokines (Peprotech). Five days later, the cells were counted and transduced using CytoTune®-iPS 2.0 Sendai reprogramming vectors (Thermo Fisher) following the manufacturer's instruction. The transduced cells were then plated onto irradiated mouse embryonic fibroblasts (MEFs) and cultured in mTeSR™1 medium (Stem Cell Technologies) which was changed every other day. Around day19 post-transduction, ESC-like colonies appeared and were manually picked on day25 post-transduction. The iPSCs were cultured on Matrigel (Corning)-coated plates in mTeSR™1 medium at 37 °C with 5% CO~2~ and routinely passaged at 1:3 ratio using dispase (Stem Cell Technologies) every 4--6 days. The iPSCs were frozen in CryoStor® CS10 freezing medium and thawed with 10 μM Y-27632 (Stem Cell Technologies). hESC (H7 \[Wi Cell Research Institute, Madison, WI, USA\]) was cultured in parallel with FDEENTi002-A.

Alkaline phosphatase (AP) staining {#S6}
----------------------------------

Cells were fixed in 4% PFA for 1--2 min, and stained for alkaline phosphatase according to Alkaline Phosphatase Detection Kit protocol (Innovative Cellular Therapeutics, China).

Immunocytochemistry {#S7}
-------------------

Cells were fixed in 4% PFA for 15 min, permeabilized with 0.3% Triton X-100 for 15 min, and blocked in 4% bovine serum albumin (BSA) for 30 min at room temperature. Then, they were treated with primary antibodies at 4 °C overnight and stained with secondary antibodies for 1 h at room temperature. Both primary and secondary antibodies were diluted in 1% BSA. Nuclei were stained with Hoechst (Thermo Fisher) for 5 min at room temperature. Images were taken by inverted fluorescence microscope (Leica Microsystems, Germany). Antibodies used are listed in [Table 2](#T2){ref-type="table"}.

In vitro spontaneous differentiation {#S8}
------------------------------------

The iPSCs ready for differentiation were cultured to around 70% confluency. Then, they were harvested using ACCUTASE™ (Stem Cell Technologies) and plated for trilineage differentiation according to the STEMdiff™ Trilineage Differentiation Kit protocol (Stem Cell Technologies). Five or seven days later, the cells were fixed for assessing lineage specific markers by immunocytochemistry.

RT-PCR and qPCR analysis {#S9}
------------------------

Total RNA was extracted using TRIzol® Reagent (Thermo Fisher). 500 ng RNA was reverse transcribed into cDNA using PrimeScript™ RT Master Mix (Takara). RT-PCR was performed on the S1000 Thermal Cycler (BIO-RAD) using EasyTaq® PCR SuperMix (Transgen, China) and analyzed by agarose gel electrophoresis. The cycle parameters were as follows: 95 °C for 5 min followed by 35 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s. qPCR was conducted on ViiA™ 7 Real-Time PCR System (Applied Biosystems) and analyzed using the ΔΔCT method. Primers used are listed in [Table 2](#T2){ref-type="table"}.

BEST1 mutation analysis {#S10}
-----------------------

gDNA was extracted from FDEENTi002-A cells using a commercial kit from CORNING (AP-EMN-BL-GDNA-250G). The mutation region of BEST1 exon 8 was amplified by PCR on the S1000 Thermal Cycler (BIORAD) using EasyTaq® PCR SuperMix (Transgen, China). The primers used are listed in [Table 2](#T2){ref-type="table"}. Sequencing of the PCR products (531 bp) was performed by Sangon Biotech (Shanghai) Co., Ltd..

Karyotyping {#S11}
-----------

FDEENTi002-A cells in the logarithmic phase at passage 8 were treated with colchicine for 4 h and then dissociated into single cells using Accutase (Stem Cell Technologies). The standard G-banding karyotyping was performed by KingMed Diagnostics, Shanghai and 20 metaphase spreads were counted.

Short tandem repeat (STR) analysis {#S12}
----------------------------------

gDNA was extracted using a commercial kit from CORNING (APEMN-BL-GDNA-250G). STR analysis was performed on the PBMCs and established iPSCs with detection of 20 loci (D3S1358, D8S1179, D19S433, AMEL, VWA, D21S11, TH01, D5S818, D7S820, D16S539, D13S317, D12S391, CSF1PO, D2S1338, TPOX, FGA, PENTAE, PENTAD, D18S51, D6S1043) by Shanghai Biowing Applied Biotechnology Co, LTD, China.

Mycoplasma test {#S13}
---------------

The absence of mycoplasma was regularly assessed by EZ-PCR Mycoplasma Test Kit (Biological Industries, BI) following the manufacturer's instruction.
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###### 

Characterization and validation.

  Classification                        Test                                        Result                                                                                         Data
  ------------------------------------- ------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------
  Morphology                            Photography                                 Normal                                                                                         [Fig. 1](#F1){ref-type="fig"} panel A
  Phenotype                             Qualitative analysis: Immunocytochemistry   Positive for pluripotency markers: OCT4, SOX2, NANOG                                           [Fig. 1](#F1){ref-type="fig"} panel F
                                        Quantitative analysis: RT-qPCR              Positive for pluripotency markers: OCT4, SOX2, NANOG                                           [Fig. 1](#F1){ref-type="fig"} panel E
  Genotype                              Karyotype (G-banding) and resolution        46XY, Resolution 400                                                                           [Fig. 1](#F1){ref-type="fig"} panel D
  Identity                              Microsatellite PCR (mPCR) OR                N/A                                                                                            N/A
                                        STR analysis                                20 loci tested, 100% matched                                                                   Available with authors.
  Mutation analysis (if applicable)     Sequencing                                  Heterozygous, c.888C \> A mutation in *BEST1* gene                                             [Fig. 1](#F1){ref-type="fig"} panel C
                                        Southern Blot OR WGS                        Not performed                                                                                  N/A
  Microbiology and virology             Mycoplasma                                  Mycoplasma testing by RT-PCR: Negative                                                         [Fig. 1](#F1){ref-type="fig"} panel I
  Differentiation potential             Directed differentiation                    Proof of three germ layers formation: ectoderm (PAX6), mesoderm (MESP1) and endoderm (FOXA2)   [Fig. 1](#F1){ref-type="fig"} panel G
  Donor screening (optional)            HIV 1 + 2 Hepatitis B, Hepatitis C          Not performed                                                                                  N/A
  Genotype additional info (optional)   Blood group genotyping HLA tissue typing    Not performed                                                                                  N/A
  Genotype additional info (optional)   Blood group genotyping HLA tissue typing    Not performed                                                                                  N/A

###### 

Reagents details.

                            Antibody                             Dilution   Company Cat \# and RRID
  ------------------------- ------------------------------------ ---------- ----------------------------------------------------------
  Pluripotency markers      Rabbit anti-OCT4                     1:200      Abcam Cat\# ab181557, RRID: AB_2687916
  Pluripotency markers      Rabbit anti-SOX2                     1:200      Abcam Cat\# ab92494, RRID: AB_10585428
  Pluripotency markers      Rabbit anti-NANOG                    1:100      Abcam Cat\# ab21624, RRID: AB_446437
  Differentiation markers   Rabbit anti-PAX6                     1:200      Abcam Cat\# ab195045, RRID: AB_2750924
  Differentiation markers   Mouse anti-MESP1                     1:200      Abcam Cat\# ab77013, RRID: AB_1566419
  Differentiation markers   Rabbit anti-FOXA2                    1:200      Abcam Cat\# ab108422, RRID: AB_11157157
  Secondary antibodies      AlexaFlour488 goat anti-mouse IgG    1:1000     Thermo Fisher Scientific Cat\# A-11001, RRID: AB_2534069
  Secondary antibodies      AlexaFlour488 goat anti-rabbit IgG   1:1000     Thermo Fisher Scientific Cat\# A-11008, RRID: AB_143165
  Secondary antibodies      AlexaFlour555 goat anti-mouse IgG    1:1000     Thermo Fisher Scientific Cat\#A-21422, RRID: AB_2535844
                                                                            

###### 

Resource table

  --------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Unique stem cell line identifier        FDEENTi002-A
  Alternative name(s) of stem cell line   XTW-C5
  Institution                             Eye & ENT Hospital, Shanghai Medical School, Fudan University, Shanghai, China
  Contact information of distributor      Xinyue Bai, <xinyue_bai@126.com>, Ling Chen, <linglingchen98@hotmail.com>
  Type of cell line                       iPSC
  Origin                                  Human
  Additional origin info                  Age: 44
                                          Sex: male
                                          Ethnicity: Han Chinese
  Cell Source                             Peripheral blood mononuclear cells (PBMCs)
  Clonality                               Clonal
  Method of reprogramming                 Transgene free, Sendai viral vectors
  Genetic modification                    YES
  Type of modification                    Spontaneous mutation
  Associated disease                      Best's disease
  Gene/locus                              BEST1 gene/11q12.3, mutation: c.888C \> A
  Method of modification                  N/A
  Name of transgene or resistance         N/A
  Inducible/constitutive system           N/A
  Date archived/stock date                1st May 2018
  Cell line repository/bank               <https://hpscreg.eu/cell-line/FDEENTi002-A>
  Ethical approval                        This study was approved by the ethics committee of Fudan University affiliated Eye & ENT Hospital (KJ2011--04).
  --------------------------------------- -----------------------------------------------------------------------------------------------------------------
